uniQure N.V. (QURE) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ultragenyx Pharmaceutical (RARE) has outperformed uniQure N.V. (QURE) over the past year, losing 50.5% versus a loss of 62.4%. Over five years, QURE leads with a -25.0% price change compared with -80.9% for RARE. uniQure N.V. is the larger company by market cap ($1.57 billion vs $1.53 billion), about 1.0 times the size, while Ultragenyx Pharmaceutical is growing revenue faster (+20.2% vs -40.6%).
Ultragenyx Pharmaceutical converts more of its revenue into profit, with a net margin of -85.4% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QURE | RARE |
|---|---|---|
| Share price | $22.59 | $15.48 |
| Market cap | $1.57B | $1.53B |
| 1-day change | +0.22% | +1.24% |
| YTD return | -5.81% | -33.52% |
| 1-year return | -62.41% | -50.45% |
| 5-year return | -25.02% | -80.89% |
| Forward P/E | — | 22.87 |
| EPS (TTM) | $-4.03 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $16.10M | $673.00M |
| Revenue growth (YoY) | -40.64% | +20.18% |
| Net income (latest FY) | $-198.97M | $-575.00M |
| Gross margin | 89.53% | — |
| Operating margin | -1151.38% | -79.49% |
| Net margin | -1236.00% | -85.44% |
| 52-week high | $71.50 | $39.89 |
| 52-week low | $8.73 | $12.73 |
| Distance from 52-week high | -68.41% | -61.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +175.92% | +81.20% |
| Average volume | 1.97M | 3.87M |
| Shares outstanding | 69.37M | 98.59M |
| Employees | 221 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RARE has outperformed QURE by 12.0 percentage points over the past year.
- Ultragenyx Pharmaceutical is more profitable, keeping -85.4 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- Ultragenyx Pharmaceutical grew revenue faster in its latest fiscal year (+20.18% vs -40.64%).
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
QURE vs RARE FAQ
Which is bigger, uniQure N.V. or Ultragenyx Pharmaceutical?
uniQure N.V. (QURE) is larger, with a market capitalization of $1.57B compared with $1.53B for Ultragenyx Pharmaceutical (RARE).
Which stock has performed better over the past year, QURE or RARE?
RARE returned -50.45% over the past 12 months, compared with -62.41% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are uniQure N.V. and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.